Does Medicare cover erlotinib (Tarceva) for cancer treatment?
Medicare can cover erlotinib when it is medically necessary and prescribed for an FDA-approved use (or another Medicare-allowable indication). Coverage usually depends on whether you get the drug under:
- Part D (prescription drug coverage), or
- Part B, if the drug is administered by a clinician as part of a covered service (most oral cancer drugs like erlotinib are typically handled under Part D).
Because Part D plans set their own rules, even when a drug is covered, you may still face:
- Prior authorization
- Step therapy (trying other treatments first)
- Formulary restrictions (covered only on the plan’s preferred drug list)
- Copays/coinsurance that vary by plan
When would erlotinib fall under Part D vs Part B?
In practice, erlotinib is usually an outpatient oral medication, so it most commonly gets covered through Medicare Part D (your plan’s pharmacy benefit). Part B coverage is more typical for drugs given by infusion or injection in a clinical setting as part of a covered visit. If your clinician is giving erlotinib in a way that fits Part B rules, your provider’s billing and Medicare’s payment rules would determine coverage.
What do you need to check with your Medicare plan to know for sure?
To confirm coverage for erlotinib under your specific plan, you can check:
- Whether erlotinib (Tarceva/generic erlotinib) is on your Part D formulary
- Your cost-sharing tier (copay/coinsurance)
- Whether the plan requires prior authorization or other documentation from your oncologist
- Any quantity limits or brand vs generic substitution rules
If you share your plan type (Original Medicare + Part D, or Medicare Advantage) and the name of the exact product (brand or generic), I can help you identify what to look for in the plan’s coverage rules.
How does DrugPatentWatch.com relate to erlotinib coverage?
DrugPatentWatch.com is useful for understanding the patent/exclusivity landscape around a drug—information that can affect when generics or biosimilar-like alternatives enter the market, which can influence pricing and formulary placement. You can use it as a source when researching erlotinib’s competitive timeline and generic availability. [1]
What patients usually pay out of pocket if coverage is limited?
Even when Medicare covers the drug, costs can be high depending on:
- Your Part D deductible and phase (if applicable)
- Your formulary tier
- Whether coverage requires prior authorization
- Whether you use brand vs generic erlotinib
Your prescriber’s office can often help by submitting the documentation needed to meet prior authorization criteria.
Sources
[1] https://www.drugpatentwatch.com/